Pay in 4 interest-free payments of $6.99 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
January 2026: Amgen completed Phase 3 enrollment for MariTide (AMG 133) in the MARITIME-Obesity trial, with interim efficacy data expected in Q3 2026 that will position the monthly injection GLP-1/GIP antagonist as a once-monthly obesity treatment alternative
PI3K/Akt/mTOR activation Hits the central anabolic signalling cascade - the same pathway behind insulin's metabolic effects and most growth-factor-driven hypertrophy
When administered the peptide, mice with moderate AD exhibited a reduced level of amyloid beta plaques in the brain, improved cognitive functionality and synaptic transmission, and protection against neuronal death
Lecithin: Lecithin comes in animal and vegetable forms, with the latter being safer
